Prevention of bleeding in hemophilia patients with high-titer inhibitors

Prevention of bleeding in hemophilia patients with high-titer inhibitors

Author Leissinger, Cindy A. Google Scholar
Konkle, Barbara A. Google Scholar
Antunes, Sandra V. Autor UNIFESP Google Scholar
Institution Tulane Univ
Blood Works NW
Univ Washington
Universidade Federal de São Paulo (UNIFESP)
Abstract Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complications, particularly arthropathy and physical disability. Three randomized clinical trials in patients with inhibitors have demonstrated that compared with on-demand bypassing therapy, prophylaxis with a bypassing agent reduces joint and other types of bleeding and improves health-related quality of life. in hemophilia patients without inhibitors, the initiation of prophylaxis with factor (F) VIII or IX prior to the onset of recurrent hemarthroses can prevent the development of joint disease. Whether this is also true for bypassing agent prophylaxis remains to be determined.
Keywords activated prothrombin complex concentrate
bypassing agents
factor IX
factor VIII
hemophilia A
hemophilia B
recombinant activated factor VII
Language English
Sponsor Baxter
CSL Behring
Novo Nordisk
Baxter Healthcare Corp
Date 2015-06-01
Published in Expert Review of Hematology. London: Expert Reviews, v. 8, n. 3, p. 375-382, 2015.
ISSN 1747-4086 (Sherpa/Romeo, impact factor)
Publisher Expert Reviews
Extent 375-382
Access rights Closed access
Type Review
Web of Science ID WOS:000354389000013

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account